Additional file 1: Table S1. of Meta-analysis of transcriptomic responses as a means to identify pulmonary disease outcomes for engineered nanomaterials

A list of 2334 differentially expressed genes that were consistent to all of the microarray platforms employed in the studies included in the meta-analysis. (PPTX 123 kb

Additional file 1: Table S1. of Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes

Particle physicochemical properties and exposure information. (XLSX 10 kb

Additional file 4: Table S3. of Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes

Details of rodent studies considered by NIOSH in calculating points of departure (PODs). (DOCX 15 kb

Additional file 3: Figure S1. of Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes

Heatmap showing the dose at which each pathway was significantly perturbed. Each column represents a post-exposure time point for the denoted MWCNT, and each row represents a signifncatly perturbed pathway. All colored cells represent the lowest dose at which the pathway is perturbed. Blank cells represent pathways that were not significantly perturbed. (PPTX 76 kb

Additional file 2: Table S2. of Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes

List of all significant pathways associated with the molecular initiating event (MIE), each key event (KE), and each associative event (AE) including the benchmark dose (BMD) value (BMDL values included in parentheses) for each MWCNT investigated at each time-point. n.a. indicates the BMD(L) could not be calculated due to poor model fit. (XLSX 18 kb